XML 102 R19.htm IDEA: XBRL DOCUMENT

Reorganization Costs	12 Months Ended
Dec. 31, 2012
Restructuring and Related Activities [Abstract]
Reorganization Costs Disclosure	5. Reorganization costs Establishment of an International Commercial Hub in Switzerland In March 2010 the Company initiated operations in Switzerland to support its HGT and SP businesses outside the US. The transition to the international commercial hub in Switzerland was completed in 2011, and resulted in total reorganization costs of $33.8 million incurred since March 2010. In the year to December 31, 2011 the Company incurred reorganization costs totaling $12.5 million (2010: $21.3 million) relating to employee involuntary termination benefits and other re-organization costs. Owings Mills In March 2009 the Company initiated plans to phase out operations and close its SP manufacturing facility at Owings Mills, Maryland. In 2011 the Company sold its Owings Mills facility and completed the transition of all products manufactured at this site to DSM Pharmaceuticals, Inc., resulting in total reorganization costs of $37.5 million incurred since March 2009. In the year ended December 31, 2011 the Company incurred reorganization costs of $11.8 million (2010: $13.0 million) which relate to employee involuntary termination benefits and other costs.

Reorganization Costs

12 Months Ended

Dec. 31, 2012

Restructuring and Related Activities [Abstract]

5. Reorganization costs

Establishment of an International Commercial Hub in Switzerland

In March 2010 the Company initiated operations in Switzerland to support its HGT and SP businesses outside the US. The transition to the international commercial hub in Switzerland was completed in 2011, and resulted in total reorganization costs of $33.8 million incurred since March 2010. In the year to December 31, 2011 the Company incurred reorganization costs totaling $12.5 million (2010: $21.3 million) relating to employee involuntary termination benefits and other re-organization costs.

Owings Mills

In March 2009 the Company initiated plans to phase out operations and close its SP manufacturing facility at Owings Mills, Maryland. In 2011 the Company sold its Owings Mills facility and completed the transition of all products manufactured at this site to DSM Pharmaceuticals, Inc., resulting in total reorganization costs of $37.5 million incurred since March 2009. In the year ended December 31, 2011 the Company incurred reorganization costs of $11.8 million (2010: $13.0 million) which relate to employee involuntary termination benefits and other costs.

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References+ Details